Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 3/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 4/20 | 0.38 |
| ▸ | HTR1D | P28221 | 2/20 | 0.38 |
| ▸ | HTR7 | P34969 | 2/20 | 0.38 |
| ▸ | HTR5A | P47898 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3019670 | 0.81 | ADRA1A (0.47) | KMT2ATSHRTP53ALDH1A1KDM4E | |
| SCHEMBL29750491 | 0.81 | ADRA1A (0.47) | KMT2ATSHRTP53ALDH1A1KDM4E | |
| SCHEMBL6484237 | 0.79 | HTR2C (0.50) | MEN1KMT2ATSHRHTR2CHTR2A | |
| SCHEMBL935859 | 0.79 | HTR2C (0.50) | MEN1KMT2ATSHRHTR2CHTR2A | |
| SCHEMBL29474981 | 0.79 | HTR2C (0.50) | MEN1KMT2ATSHRHTR2CHTR2A | |
| SCHEMBL27845790 | 0.78 | TSHR (0.44) | TSHRHTR2CHTR2AHTR2BHTR1A | |
| SCHEMBL17755141 | 0.77 | ADRA2A (0.55) | HDAC4MEN1KMT2AATMIRAK4 | |
| SCHEMBL11302784 | 0.74 | HTR2B (0.55) | MEN1KMT2ATSHRSMN1; SMN2NPSR1 | |
| SCHEMBL8619634 | 0.74 | CXCR5 (0.35) | MEN1KMT2ATSHRLMNATP53 | |
| SCHEMBL12313576 | 0.73 | ADRA2A (0.58) | HDAC4MEN1KMT2AATMHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472374-B2 | ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2019-11-12 | — | — | US | disclosed |
| EP-3329919-B1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO LLC (US) | 2019-11-06 | — | — | EP | disclosed |
| US-20190016732-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2019-01-17 | — | — | US | disclosed |
| EP-3329919-A1 | ACC INHIBITORS AND USES THEREOF | Gilead Apollo, LLC (US) | 2018-06-06 | — | — | EP | disclosed |
| US-9944655-B2 | ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2018-04-17 | — | — | US | disclosed |
| US-9944655-B2 | ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2016-10-13 | — | — | US | disclosed |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2016-10-13 | — | — | US | disclosed |
| US-20150203510-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2015-07-23 | — | — | US | disclosed |
| US-20150203510-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2015-07-23 | — | — | US | disclosed |
| US-8969557-B2 | ACC inhibitors and uses thereof | Nimbus Apollo, Inc. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969557-B2 | ACC inhibitors and uses thereof | Nimbus Apollo, Inc. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | US | disclosed |
| WO-2013071169-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203510-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | HDAC4 919/4885MEN1 4200/4885KMT2A 2071/4885 |
| US-10472374-B2 | ACC inhibitors and uses thereof | ACACA, ACACB, ACAT2 | HDAC4 919/4885MEN1 4200/4885KMT2A 2071/4885 |
| US-20190016732-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | HDAC4 919/4885MEN1 4200/4885KMT2A 2071/4885 |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | HDAC4 919/4885MEN1 4200/4885KMT2A 2071/4885 |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | HDAC4 919/4885MEN1 4200/4885KMT2A 2071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.